Support for EphB2 functioning as a tumour suppressor in prostate cancer comes from the identification of its mutational inactivation; when DU-145 cells were transfected with a wild-type EphB2, clonogenic growth was suppressed [38]. Here, EPHB2 is linked to neoplasm.